Alterity Therapeutics Ltd has released a press release.
PBT434 at the 6th International Multiple System Atrophy Conf
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Prana receives $3 million R&D Tax Incentive Refund
- Prospectus Supplement
- Notice of Meeting/ Proxy Form
- Appendix 4E and Annual Report
- Prana commences research collaboration with Takeda
Later from Alterity Therapeutics
- Prana to commence Phase 1 clinical trial of PBT434
- First Volunteers Dosed in Phase I Clinical Trial of PBT434
- Prana to present PBT434 data at International Congress
- Annual Report to shareholders
- New data show potential for PBT434 to treat MSA
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics